Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy

AIDS

Volumn 23, Issue 13, 2009, Pages 1689-1699

  Kesselring, Anouk M ^a   Wit, Ferdinand W ^b   Sabin, Caroline A ^c   Lundgren, Jens D ^d   Gill, M John ^e   Gatell, Jose M ^f   Rauch, Andri ^g   Montaner, Julio S ^h   De Wolf, Frank ^a   Reiss, Peter ^b   Mocroft, Amanda ^c  

^a STICHTING HIV MONITORING   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF BARCELONA   (Spain)

^g UNIVERSITY OF BERN   (Switzerland)

^h ST PAUL S HOSPITAL   (Canada)

Author keywords

CD4 cell count; HIV; Nevirapine; Toxicity; Viral load

Indexed keywords

ABACAVIR; LAMIVUDINE; NEVIRAPINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LACTIC ACIDOSIS; LIVER TOXICITY; PANCREAS DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG HYPERSENSITIVITY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 69449103829     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832d3b54     Document Type: Article

References (37)

1. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. U.S. Department of Health and Human Services (DHHS). BETA 1997:11-22.
2. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998; 279:930-937. (Pubitemid 28136082)
3. Carr A, Vella S, de J, Sorice F, Imrie A, Boucher CA, et al. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group. AIDS 1996; 10:635-641. (Pubitemid 26162992)
4. D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Liou SH, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med 1996; 124:1019-1030.
5. de J, Vella S, Carr A, Boucher CA, Imrie A, French M, et al. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis 1997; 175:966-970. (Pubitemid 27142979)
6. Cattelan AM, Erne E, Salatino A, Trevenzoli M, Carretta G, Meneghetti F, et al. Severe hepatic failure related to nevirapine treatment. Clin Infect Dis 1999; 29:455-456. (Pubitemid 29380226)
7. Leitze Z, Nadeem A, Choudhary A, Saul Z, Roberts I, Manthous CA. Nevirapine-induced hepatitis treated with corticosteroids? AIDS 1998; 12:1115-1117.
8. Warren KJ, Boxwell DE, Kim NY, Drolet BA. Nevirapine-associated Stevens-Johnson syndrome. Lancet 1998; 351:567.
9. Descamps V, Tattevin P, Descamps D, L'Heriteau F, Schortgen F, Regnier B. HIV-1 infected patients with toxic epidermal necrolysis: an occupational risk for healthcare workers. Lancet 1999; 353:1855-1856. (Pubitemid 29251028)
10. Barner A, Myers M. Nevirapine and rashes. Lancet 1998; 351:1133.
11. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures: worldwide, '97-'00. HIV Clin 2001; 13:11.
12. Ananworanich J, Moor Z, Siangphoe U, Chan J, Cardiello P, Duncombe C, et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS 2005; 19:185-192. (Pubitemid 40409537)
13. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35:538-539.
14. Mocroft A, Staszewski S, Weber R, Gatell J, Rockstroh J, Gasiorowski J, et al. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts. Antivir Ther 2007; 12:325-333. (Pubitemid 46787977)
15. Wit FW, Kesselring AM, Gras L, Richter C, van der Ende ME, Brinkman K, et al. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study. Clin Infect Dis 2008; 46:933-940.
16. 3 or greater. J Acquir Immune Defic Syndr 2007; 45:183-192.
17. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730. (Pubitemid 28534954)
18. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005; 6:99-106.
19. The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5:115-124.
20. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357:592-598. (Pubitemid 32179612)
21. Phillips E, Gutierrez S, Jahnke N, Yip B, Lima VD, Hogg RS, et al. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients. AIDS 2007; 21:1561-1568. (Pubitemid 47075477)
22. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-868. (Pubitemid 29126872)
23. De Lazzari E, Leon A, Arnaiz JA, Martinez E, Knobel H, Negredo E, et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. HIV Med 2008; 9:221-226.
24. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS2000; 14:807-812.
25. Dieleman JP, Sturkenboom MC, Wit FW, Jambroes M, Mulder JW, ten Veen JH, et al. Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression. J Infect Dis 2002; 185:1261-1268. (Pubitemid 34439133)
26. Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19:97-99. (Pubitemid 40111026)
27. Gatanaga H, Yazaki H, Tanuma J, Honda M, Genka I, Teruya K, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007; 21:264-265. (Pubitemid 46036947)
28. Littera R, Carcassi C, Masala A, Piano P, Serra P, Ortu F, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 2006; 20:1621-1626. (Pubitemid 44162404)
29. Shenton JM, Popovic M, Chen J, Masson MJ, Uetrecht JP. Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat. Chem Res Toxicol 2005; 18:1799-1813. (Pubitemid 43023038)
30. Pirmohamed M, Park BK. HIV and drug allergy. Curr Opin Allergy Clin Immunol 2001; 1:311-316.
31. Rauch A, Nolan D, Thurnheer C, Fux CA, Cavassini M, Chave JP, et al. Refining abacavir hypersensitivity diagnosis using a structural clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antivir Ther 2008; 13:1019-1028.
32. Bersoff-Matcha SJ, Miller WC, Aberg JA, van Der HC, Hamrick HJ Jr, Powderly WG, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32:124-129.
33. Antinori A, Baldini F, Girardi E, Cingolani A, Zaccarelli M, Di GS, et al. Female sex and the use of antiallergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 2001; 15:1579-1581. (Pubitemid 32744607)
34. van LF, Andrews S, Grinsztejn B, Wilkins E, Lazanas MK, Lange JM, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19:463-471. (Pubitemid 40515849)
35. Ho TT, Wong KH, Chan KC, Lee SS. High incidence of nevirapine-associated rash in HIV-infected Chinese. AIDS 1998; 12:2082-2083.
36. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191:825-829. (Pubitemid 40349795)
37. Kappelhoff BS, van LF, Robinson PA, MacGregor TR, Baraldi E, Montella F, et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther 2005; 10:489-498.